Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
8 participants
INTERVENTIONAL
2018-12-06
2019-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effect of Real-time Continuous Glucose Monitoring on Severe Complications to Pregnancy in Women With Diabetes
NCT00994357
Pilot Study of Glycemic Control in Diabetic Hemodialyzed Patients
NCT01828970
Evaluation of Glucose Monitoring Methods: Characterizing Glycemic Control in Subjects With Diabetes
NCT00805506
National Trial of CGM in Pregnant Women With Type 2 Diabetes
NCT06903728
Three Approaches to Glucose Monitoring in Non-insulin Treated Diabetes
NCT02033499
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Six study hyperglycemic clamps (10 mmol/l) pr. participant.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo+placebo
Saline infusions
Saline
Placebo (vehicle for infusions)
GIP+placebo
GIP(1-42), receptor agonist
GIP receptor agonist
GIP(1-42)
Saline
Placebo (vehicle for infusions)
GIP+dose 1
GIP(1-42) and lowest dose of GIP(3-30)NH2
GIP receptor antagonist
GIP receptor antagonist
GIP receptor agonist
GIP(1-42)
GIP+dose 2
GIP(1-42) and dose of GIP(3-30)NH2
GIP receptor antagonist
GIP receptor antagonist
GIP receptor agonist
GIP(1-42)
GIP+dose 3
GIP(1-42) and dose of GIP(3-30)NH2
GIP receptor antagonist
GIP receptor antagonist
GIP receptor agonist
GIP(1-42)
GIP+dose4
GIP(1-42) and highest dose of GIP(3-30)NH2
GIP receptor antagonist
GIP receptor antagonist
GIP receptor agonist
GIP(1-42)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GIP receptor antagonist
GIP receptor antagonist
GIP receptor agonist
GIP(1-42)
Saline
Placebo (vehicle for infusions)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI 19-28 kg/m\*m
* Stable body weight
Exclusion Criteria
* Anemia
* First-degree relatives with diabetes
18 Years
70 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Steno Diabetes Center Copenhagen
OTHER
University of Copenhagen
OTHER
University Hospital, Gentofte, Copenhagen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Lærke Smidt Gasbjerg
MD
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinical Metabolic Physiology
Gentofte Municipality, Copenhagen, Denmark
Clinical Metabolic Physiology
Copenhagen, Gentofte, Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SDCC_CMP_GA-10
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.